S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
DIS   146.10 (-0.08%)
Log in

NASDAQ:NVTR - Nuvectra Stock Price, Forecast & News

$0.13
-0.02 (-13.33 %)
(As of 12/10/2019 04:00 PM ET)
Today's Range
$0.13
Now: $0.13
$0.13
50-Day Range
$0.13
MA: $0.75
$1.79
52-Week Range
$0.13
Now: $0.13
$20.85
VolumeN/A
Average Volume2.43 million shs
Market Capitalization$2.33 million
P/E RatioN/A
Dividend YieldN/A
Beta0.69
Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NVTR
Previous SymbolNASDAQ:NVTRV
CUSIPN/A
Phone214-474-3103

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$48.83 million
Book Value$5.28 per share

Profitability

Net Income$-48,130,000.00

Miscellaneous

Employees197
Market Cap$2.33 million
Next Earnings DateN/A
OptionableOptionable

Receive NVTR News and Ratings via Email

Sign-up to receive the latest news and ratings for NVTR and its competitors with MarketBeat's FREE daily newsletter.


Nuvectra (NASDAQ:NVTR) Frequently Asked Questions

What is Nuvectra's stock symbol?

Nuvectra trades on the NASDAQ under the ticker symbol "NVTR."

How were Nuvectra's earnings last quarter?

Nuvectra Corp (NASDAQ:NVTR) announced its quarterly earnings data on Monday, October, 29th. The company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.86) by $0.01. The firm earned $14.22 million during the quarter, compared to analyst estimates of $12.38 million. Nuvectra had a negative net margin of 99.08% and a negative return on equity of 58.23%. View Nuvectra's Earnings History.

What price target have analysts set for NVTR?

3 Wall Street analysts have issued 12 month price objectives for Nuvectra's shares. Their forecasts range from $4.00 to $18.00. On average, they expect Nuvectra's stock price to reach $10.67 in the next twelve months. This suggests a possible upside of 8,105.1% from the stock's current price. View Analyst Price Targets for Nuvectra.

What is the consensus analysts' recommendation for Nuvectra?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvectra in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nuvectra.

Has Nuvectra been receiving favorable news coverage?

Media coverage about NVTR stock has been trending somewhat positive this week, according to InfoTrie. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nuvectra earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Nuvectra.

Who are some of Nuvectra's key competitors?

What other stocks do shareholders of Nuvectra own?

Who are Nuvectra's key executives?

Nuvectra's management team includes the folowing people:
  • Dr. Fred B. Parks Ph.D., CEO & Director (Age 72)
  • Mr. Joseph Paul Hanchin, Pres (Age 57)
  • Mr. Walter Z. Berger, COO, CFO & Exec. VP (Age 63)
  • Ms. Jennifer J. Kosharek, VP, Controller & Principal Accounting Officer (Age 38)
  • Mr. Benjamin Tranchina, Chief Technology Officer

Who are Nuvectra's major shareholders?

Nuvectra's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (1.40%), Gabelli Funds LLC (1.18%), Essex Investment Management Co. LLC (0.91%), Gamco Investors INC. ET AL (0.59%), Edge Wealth Management LLC (0.28%) and Millennium Management LLC (0.15%). Company insiders that own Nuvectra stock include Benjamin Tranchina, David D Johnson, Joseph Paul Hanchin and Thomas Edward Zelibor. View Institutional Ownership Trends for Nuvectra.

Which major investors are selling Nuvectra stock?

NVTR stock was sold by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Millennium Management LLC, Essex Investment Management Co. LLC and SG Americas Securities LLC. View Insider Buying and Selling for Nuvectra.

Which major investors are buying Nuvectra stock?

NVTR stock was bought by a variety of institutional investors in the last quarter, including Gabelli Funds LLC, Gamco Investors INC. ET AL, Valeo Financial Advisors LLC and Edge Wealth Management LLC. Company insiders that have bought Nuvectra stock in the last two years include Benjamin Tranchina, David D Johnson and Thomas Edward Zelibor. View Insider Buying and Selling for Nuvectra.

How do I buy shares of Nuvectra?

Shares of NVTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Nuvectra's stock price today?

One share of NVTR stock can currently be purchased for approximately $0.13.

How big of a company is Nuvectra?

Nuvectra has a market capitalization of $2.33 million and generates $48.83 million in revenue each year. The company earns $-48,130,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Nuvectra employs 197 workers across the globe.View Additional Information About Nuvectra.

What is Nuvectra's official website?

The official website for Nuvectra is http://www.nuvectramed.com/.

How can I contact Nuvectra?

Nuvectra's mailing address is 5830 GRANITE PKWY SUITE 1100, PLANO TX, 75024. The company can be reached via phone at 214-474-3103 or via email at [email protected]


MarketBeat Community Rating for Nuvectra (NASDAQ NVTR)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  429
MarketBeat's community ratings are surveys of what our community members think about Nuvectra and other stocks. Vote "Outperform" if you believe NVTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Featured Article: What is a CD ladder?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel